Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction (CRIDD)
Primary Purpose
Cardiac Surgery, Cardiopulmonary Bypass
Status
Active
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Eurosets REMOWELL 2 oxygenator
LivaNova INSPIRE oxygenator
Sponsored by
About this trial
This is an interventional treatment trial for Cardiac Surgery
Eligibility Criteria
Inclusion Criteria:
- Signature of informed consent for participation in the study
- Age ≥65 years
Patients undergoing cardiac surgery of:
- coronary artery bypass graft and concomitant valve replacement/repair OR
- double valve replacement/repair
Exclusion Criteria:
- Any documented history of cognitive impairment estimated as a mini mental state examination < 24 points
- Patients who need blood prime in the cardiopulmonary bypass circuit
- Chronic coagulopathies ( international normalized ratio > 2 in patients without anticoagulant treatment)
- End stage renal disease on dialysis treatment
- Previous cerebrovascular accident
- Active cancer or immunological diseases
- Liver cirrhosis (platelets <100.000/uL)
- Decompensated diabetes
- Severe preoperative anemia (hemoglobin <8 g/dl).
Sites / Locations
- Maria Cecilia Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Eurosets REMOWELL 2 oxygenator
LivaNova INSPIRE oxygenator
Arm Description
Outcomes
Primary Outcome Measures
post-operative delirium
In-hospital incidence of post-operative delirium assessed by Confusion Assessment Method (CAM) diagnostic algorithm
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04062396
Brief Title
Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction
Acronym
CRIDD
Official Title
Randomized Comparison Between Oxygenator Systems for the Reduction of Post-operative Delirium in Older Patients Undergoing Cardiac Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
September 26, 2019 (Actual)
Primary Completion Date
June 26, 2022 (Actual)
Study Completion Date
September 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maria Cecilia Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Age is no longer an absolute contraindication to cardiac surgery therefore there is often need for combined interventions (double valve repair/replacement, or coronary artery bypass graft and valve repair/replacement) with relative prolongation of cardiopulmonary bypass time. Prolonged cardiopulmonary bypass use causes an increase in the inflammatory response, and on the other a need for blood reinfusion and therefore lipid microemboli from the operative field. The clinical consequences for patients are post-operative delirium and post-operative cognitive impairment.
These two neurological complications involve up to 45% of elderly patients undergoing cardiac surgery and have a significant impact on quality of life, hospitalization and mortality in the short and long term. The Remowell 2 oxygenator system has demonstrated in preliminary studies that, compared to the gold standard Inspire oxygenator, it can guarantee a significant reduction of hemodilution, inflammatory systemic response and embolization of lipid microemboli and leukocytes. In light of these considerations, it is possible to formulate the hypothesis that the use of the Remowell 2 device can contribute to significantly reducing the onset of post-operative delirium and cognitive impairment. The present study is designed to validate this hypothesis in a randomized controlled scenario.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Surgery, Cardiopulmonary Bypass
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
314 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Eurosets REMOWELL 2 oxygenator
Arm Type
Active Comparator
Arm Title
LivaNova INSPIRE oxygenator
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Eurosets REMOWELL 2 oxygenator
Intervention Description
The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion
Intervention Type
Device
Intervention Name(s)
LivaNova INSPIRE oxygenator
Intervention Description
INSPIRE oxygenator has no filtration system for extracavitary inlet
Primary Outcome Measure Information:
Title
post-operative delirium
Description
In-hospital incidence of post-operative delirium assessed by Confusion Assessment Method (CAM) diagnostic algorithm
Time Frame
6 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signature of informed consent for participation in the study
Age ≥65 years
Patients undergoing cardiac surgery of:
coronary artery bypass graft and concomitant valve replacement/repair OR
double valve replacement/repair
Exclusion Criteria:
Any documented history of cognitive impairment estimated as a mini mental state examination < 24 points
Patients who need blood prime in the cardiopulmonary bypass circuit
Chronic coagulopathies ( international normalized ratio > 2 in patients without anticoagulant treatment)
End stage renal disease on dialysis treatment
Previous cerebrovascular accident
Active cancer or immunological diseases
Liver cirrhosis (platelets <100.000/uL)
Decompensated diabetes
Severe preoperative anemia (hemoglobin <8 g/dl).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lorenzo Mantovani, MD
Organizational Affiliation
Maria Cecilia Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maria Cecilia Hospital
City
Cotignola
State/Province
Ravenna
ZIP/Postal Code
48010
Country
Italy
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction
We'll reach out to this number within 24 hrs